Skip to main content

Advertisement

SpringerLink
Log in

Should EGFR mutations be tested in advanced lung squamous cell carcinomas to guide frontline treatment?

  • Review Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

There is no argument over using epidermal growth factor receptor (EGFR) mutation status to guide the frontline treatment for advanced lung adenocarcinoma (LADC); however, the role of the testing in lung squamous cell carcinoma (LSQC) remains controversial. Currently, the guidelines/consensus statements regarding EGFR mutation testing in LSQC are not consistent among different oncology societies. American Society of Clinical Oncology recommends performing EGFR mutation testing in all patients; European Society for Medical Oncology, College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology, and National Comprehensive Cancer Network suggest for some selected group. EGFR mutation is rarely found in LSQC; however, more importantly, it is not a valid predictive biomarker for EGFR tyrosine kinase inhibitors (EGFR-TKI) in LSQC as it has been shown in LADC. Available data showed that the response rate and progression-free survival in EGFR mutant LSQC patients treated with EGFR-TKI are not better than that observed in patients treated with platinum-doublet chemotherapy in the first-line setting. Therefore, in contrast to advanced LADC, EGFR mutation testing may not be necessarily performed upfront in advanced LSQC because not only the mutation rate is low, but also the predictive value is insufficient. For LSQC patients with known sensitizing-EGFR mutations, both conventional chemotherapy and EGFR-TKI are acceptable frontline treatment options.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Pao W, Chmielecki J (2010) Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 10:760–774

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  2. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11:121–128

    Article  PubMed  CAS  Google Scholar 

  3. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380–2388

    Article  PubMed  CAS  Google Scholar 

  4. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C et al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12:735–742

    Article  PubMed  CAS  Google Scholar 

  5. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239–246

    Article  PubMed  CAS  Google Scholar 

  6. Sequist LV, Yang JC, Yamamoto N, O’Byrne K, Hirsh V, Mok T et al (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31:3327–3334

    Article  PubMed  CAS  Google Scholar 

  7. Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y et al (2014) Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 15:213–222

    Article  PubMed  CAS  Google Scholar 

  8. Chou TY, Chiu CH, Li LH, Hsiao CY, Tzen CY, Chang KT et al (2005) Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res 11:3750–3757

    Article  PubMed  CAS  Google Scholar 

  9. Shukuya T, Takahashi T, Kaira R, Shukuya T, Takahashi T, Kaira R et al (2011) Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports. Cancer Sci 102:1032–1037

    Article  PubMed  CAS  Google Scholar 

  10. Keedy VL, Temin S, Somerfield MR, Beasley MB, Johnson DH, McShane LM et al (2011) American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 29:2121–2127

    Article  PubMed  Google Scholar 

  11. Felip E, Gridelli C, Baas P, Rosell R, Stahel R, Panel Members (2011) Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO consensus conference in lung cancer; Lugano 2010. Ann Oncol 22:1507–1519

    Article  PubMed  CAS  Google Scholar 

  12. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G et al (2013) Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med 137:828–860

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  13. National Comprehensive Cancer Network (2014) NCCN clinical practice guidelines in oncology. Non-Small Cell Lung Cancer v.3.2014. http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. (Accessed 18 Mar 2014)

  14. Shigematsu H, Gazdar AF (2006) Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 118:257–262

    Article  PubMed  CAS  Google Scholar 

  15. Park K, Goto K (2006) A review of the benefit–risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer. Curr Med Res Opin 22:561–573

    Article  PubMed  CAS  Google Scholar 

  16. Hata A, Katakami N, Kunimasa K, Hata A, Katakami N, Kunimasa K et al (2011) Erlotinib for pretreated squamous cell carcinoma of the lung in Japanese patients. Jpn J Clin Oncol 41:1366–1372

    Article  PubMed  Google Scholar 

  17. Lee Y, Shim HS, Park MS, Kim JH, Ha SJ, Kim SH et al (2012) High EGFR gene copy number and skin rash as predictive markers for EGFR tyrosine kinase inhibitors in patients with advanced squamous cell lung carcinoma. Clin Cancer Res 18:1760–1768

    Article  PubMed  CAS  Google Scholar 

  18. Tseng JS, Yang TY, Chen KC, Hsu KH, Chen HY, Chang GC (2012) Retrospective study of erlotinib in patients with advanced squamous lung cancer. Lung Cancer 77:128–133

    Article  PubMed  Google Scholar 

  19. Chiang CL, Tsai CM, Chou TY, Chen YM, Lai SL, Shih JF et al (2013) Erlotinib in patients with advanced lung squamous cell carcinoma. Cancer Chemother Pharmacol 71:203–208

    Article  PubMed  CAS  Google Scholar 

  20. Wu JY, Wu SG, Yang CH, Chang YL, Chang YC, Hsu YC et al (2011) Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations. Lung Cancer 72:205–212

    Article  PubMed  Google Scholar 

  21. Hata A, Katakami N, Yoshioka H, Kunimasa K, Fujita S, Kaji R et al (2013) How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR gene-sensitive mutations? J Thorac Oncol 8:89–95

    Article  PubMed  CAS  Google Scholar 

  22. Smit EF, van Meerbeeck JP, Lianes P, Debruyne C, Legrand C, Schramel F et al (2003) Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group–EORTC 08975. J Clin Oncol 21:3909–3917

    Article  PubMed  CAS  Google Scholar 

  23. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98

    Article  PubMed  CAS  Google Scholar 

  24. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y et al (2011) International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6:244–285

    Article  PubMed  Google Scholar 

  25. Rekhtman N, Paik PK, Arcila ME, Tafe LJ, Oxnard GR, Moreira AL et al (2012) Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res 18:1167–1176

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  26. Paik PK, Varghese AM, Sima CS, Moreira AL, Ladanyi M, Kris MG et al (2012) Response to erlotinib in patients with EGFR mutant advanced non-small cell lung cancers with a squamous or squamous-like component. Mol Cancer Ther 11:2535–2540

    Article  PubMed  CAS  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan

    Chao-Hua Chiu & Teh-Ying Chou

  2. Department of Medicine, National Yang-Ming University, Taipei, Taiwan

    Chao-Hua Chiu & Chun-Ming Tsai

  3. Division of Thoracic Oncology, Department of Chest Medicine, Taipei Veterans General Hospital, 201, Section 2, Shih-Pai Road, Taipei, 11217, Taiwan

    Chao-Hua Chiu, Chi-Lu Chiang & Chun-Ming Tsai

  4. Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

    Teh-Ying Chou

Authors
  1. Chao-Hua Chiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Teh-Ying Chou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chi-Lu Chiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chun-Ming Tsai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chun-Ming Tsai.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chiu, CH., Chou, TY., Chiang, CL. et al. Should EGFR mutations be tested in advanced lung squamous cell carcinomas to guide frontline treatment?. Cancer Chemother Pharmacol 74, 661–665 (2014). https://doi.org/10.1007/s00280-014-2536-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-014-2536-3

Keywords

Search

Navigation